These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33826946)

  • 21. Fevipiprant, a selective prostaglandin D
    Hardman C; Chen W; Luo J; Batty P; Chen YL; Nahler J; Wu Y; Pavord ID; Erpenbeck VJ; Sandham DA; Xue L; Ogg G
    J Allergy Clin Immunol; 2019 Jun; 143(6):2329-2333. PubMed ID: 30825466
    [No Abstract]   [Full Text] [Related]  

  • 22. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse.
    Spik I; Brénuchon C; Angéli V; Staumont D; Fleury S; Capron M; Trottein F; Dombrowicz D
    J Immunol; 2005 Mar; 174(6):3703-8. PubMed ID: 15749909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prostaglandin D
    Domingo C; Palomares O; Sandham DA; Erpenbeck VJ; Altman P
    Respir Res; 2018 Sep; 19(1):189. PubMed ID: 30268119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fevipiprant, a DP
    Shamri R; Dubois G; Erpenbeck VJ; Mankuta D; Sandham DA; Levi-Schaffer F
    Clin Exp Allergy; 2019 Feb; 49(2):255-257. PubMed ID: 30379368
    [No Abstract]   [Full Text] [Related]  

  • 25. A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach.
    Weiss HM; Umehara KI; Erpenbeck VJ; Cain M; Vemula J; Elbast W; Zollinger M
    Drug Metab Dispos; 2020 Oct; 48(10):917-924. PubMed ID: 32739890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date.
    Kao CC; Parulekar AD
    J Asthma Allergy; 2019; 12():1-5. PubMed ID: 30662272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis.
    Jahangir A; Sattar SBA; Rafay Khan Niazi M; Muhammad M; Jahangir A; Sahra S; Sharif MA; Anwar MY; Chalhoub M
    Cureus; 2022 May; 14(5):e24641. PubMed ID: 35663651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma.
    Schmidt JA; Bell FM; Akam E; Marshall C; Dainty IA; Heinemann A; Dougall IG; Bonnert RV; Sargent CA
    Br J Pharmacol; 2013 Apr; 168(7):1626-38. PubMed ID: 23146091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
    Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Kumi RO; Olotu FA; Soliman MES
    Comb Chem High Throughput Screen; 2019; 22(8):521-533. PubMed ID: 31538888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prostaglandin D2, 15-deoxy-Delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats.
    Almishri W; Cossette C; Rokach J; Martin JG; Hamid Q; Powell WS
    J Pharmacol Exp Ther; 2005 Apr; 313(1):64-9. PubMed ID: 15590767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2.
    Yoshimura-Uchiyama C; Iikura M; Yamaguchi M; Nagase H; Ishii A; Matsushima K; Yamamoto K; Shichijo M; Bacon KB; Hirai K
    Clin Exp Allergy; 2004 Aug; 34(8):1283-90. PubMed ID: 15298571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).
    Castro M; Kerwin E; Miller D; Pedinoff A; Sher L; Cardenas P; Knorr B; Lawrence D; Ossa D; Wang W; Maspero JF
    EClinicalMedicine; 2021 May; 35():100847. PubMed ID: 33997741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils.
    Cossette C; Walsh SE; Kim S; Lee GJ; Lawson JA; Bellone S; Rokach J; Powell WS
    J Pharmacol Exp Ther; 2007 Jan; 320(1):173-9. PubMed ID: 17041009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation.
    Bain G; Lorrain DS; Stebbins KJ; Broadhead AR; Santini AM; Prodanovich P; Darlington J; King CD; Lee C; Baccei C; Stearns B; Troung Y; Hutchinson JH; Prasit P; Evans JF
    J Pharmacol Exp Ther; 2011 Jul; 338(1):290-301. PubMed ID: 21487069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the PGD
    Kupczyk M; Kuna P
    Drugs; 2017 Aug; 77(12):1281-1294. PubMed ID: 28612233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP
    Sandham DA; Barker L; Brown L; Brown Z; Budd D; Charlton SJ; Chatterjee D; Cox B; Dubois G; Duggan N; Hall E; Hatto J; Maas J; Manini J; Profit R; Riddy D; Ritchie C; Sohal B; Shaw D; Stringer R; Sykes DA; Thomas M; Turner KL; Watson SJ; West R; Willard E; Williams G; Willis J
    ACS Med Chem Lett; 2017 May; 8(5):582-586. PubMed ID: 28523115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor.
    Monneret G; Gravel S; Diamond M; Rokach J; Powell WS
    Blood; 2001 Sep; 98(6):1942-8. PubMed ID: 11535533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
    Sykes DA; Bradley ME; Riddy DM; Willard E; Reilly J; Miah A; Bauer C; Watson SJ; Sandham DA; Dubois G; Charlton SJ
    Mol Pharmacol; 2016 May; 89(5):593-605. PubMed ID: 26916831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils.
    Monneret G; Cossette C; Gravel S; Rokach J; Powell WS
    J Pharmacol Exp Ther; 2003 Jan; 304(1):349-55. PubMed ID: 12490611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.